CTSH Stock Forecast & Price Target

Cognizant Tech Solns is attractive because its Financial Services franchise is delivering double-digit growth and remains the clearest proof point for its AI-led modernization strategy, with large-deal momentum and easier comparisons expected to support a better 2H trajectory. The company’s outlook is further strengthened by visible margin support from Project Leap, which is expected to generate $200–$300 million of gross savings in FY26 and help lift adjusted operating margin to 16.0%–16.2%, while fixed-price contracts now represent roughly half of revenue. Its broader portfolio adds resilience through stable healthcare demand, improving CMT headwinds, and expanding AI, TriZetto, and Belcan opportunities, alongside strong free cash flow and balanced capital returns.

Cognizant Tech Solns is viewed negatively because its growth depends on converting a large deal pipeline into profitable revenue while facing elongated sales cycles, selective enterprise spending, and a tougher IT spending environment. The company’s reliance on offshore delivery and high-tech recruiting also leaves it exposed to H1B visa constraints, intensifying competition, and macro uncertainty that could slow revenue growth and pressure margins despite momentum in $100m+ deals and the Astreya acquisition. Although Project Leap may support margin expansion and an AI-enabled operating model, the lack of sustained revenue acceleration or stable IT budgets could prevent the firm from meeting expectations.